U

Search

Shop

w

News

w

Blog

Donate

Team Jack Foundation Awards $500,000 to Columbia University’s Robert Wechsler-Reya, PhD, for Medulloblastoma Research

Feb 11, 2025 | News

Funding from the Team Jack Foundation will aid Dr. Wechsler-Reya and his team in developing a MYC-Inhibitor for Medulloblastoma.

Project Name: Development of a Brain-Restricted MYC Inhibitor for Medulloblastoma.
Amount Funded: $500,000

The Team Jack Foundation is proud to announce a $500,000 research grant award, approved in December 2024, to Robert Wechsler-Reya, PhD from Columbia University. Dr. Wechsler-Reya’s project, if successful, will improve the outcome for children with medulloblastoma.

Medulloblastoma is an extremely aggressive pediatric brain tumor. While current treatments prolong survival, many patients die of the disease, and survivors often suffer severe long-term side effects from therapy. More effective and less toxic therapies are essential to improve outcomes for medulloblastoma patients.

One major challenge in treating brain tumors is the “blood-brain barrier”, which prevents many anti-cancer drugs from getting into the brain. To achieve sufficient levels in a brain tumor, these drugs must be given at very high doses, which are toxic to normal tissues outside the brain. This toxicity limits the amount of drug that can be given safely, reducing the effectiveness of therapy. The Team Jack award proposes to turn this problem on its head, by generating drugs that are active in the brain and not in other tissues.

Researchers at Columbia will do this using a new drug they have developed, which targets the MYC oncogene, a key driver of tumor growth in medulloblastoma. This drug can get into the brain to some degree, but it is also toxic to other tissues. By chemically modifying the drug, they can develop a version that is active in the brain (where it can stop brain tumor growth) but inactive in other tissues (so it should have fewer side effects). This will allow them to give much higher doses of the drug, and more effectively suppress growth of medulloblastoma.

This work is a collaboration between four labs with different skills and expertise, at four different institutions — Columbia University, University of California Berkeley (UCB), University of California San Francisco (UCSF), and Sanford Burnham Prebys (SBP) Medical Discovery Institute in La Jolla.

This is a very ambitious project that, if successful, will create a new paradigm for treatment of medulloblastoma. I am really excited to be working with my colleagues at Berkeley, UCSF and SBP, and extremely grateful to the Team Jack Foundation for supporting this work.

Robert Wechsler-Reya, PhD

H. Houston Merritt Professor of Neurological Sciences | Scientific Director of Brain Tumor Research,, Herbert Irving Comprehensive Cancer Center | Columbia University Medical Center